CN114007598A - 用于治疗病毒和细菌感染的新型mek抑制剂 - Google Patents

用于治疗病毒和细菌感染的新型mek抑制剂 Download PDF

Info

Publication number
CN114007598A
CN114007598A CN202080044394.4A CN202080044394A CN114007598A CN 114007598 A CN114007598 A CN 114007598A CN 202080044394 A CN202080044394 A CN 202080044394A CN 114007598 A CN114007598 A CN 114007598A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
virus
infection
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044394.4A
Other languages
English (en)
Chinese (zh)
Inventor
O·普朗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Westfaelische Wilhelms Universitaet Muenster
Original Assignee
Westfaelische Wilhelms Universitaet Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Westfaelische Wilhelms Universitaet Muenster filed Critical Westfaelische Wilhelms Universitaet Muenster
Publication of CN114007598A publication Critical patent/CN114007598A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080044394.4A 2019-04-16 2020-04-16 用于治疗病毒和细菌感染的新型mek抑制剂 Pending CN114007598A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU101183 2019-04-16
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Publications (1)

Publication Number Publication Date
CN114007598A true CN114007598A (zh) 2022-02-01

Family

ID=66554457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044394.4A Pending CN114007598A (zh) 2019-04-16 2020-04-16 用于治疗病毒和细菌感染的新型mek抑制剂

Country Status (13)

Country Link
US (1) US12350244B2 (https=)
EP (1) EP3955908B1 (https=)
JP (2) JP2022529343A (https=)
KR (1) KR20210153642A (https=)
CN (1) CN114007598A (https=)
AU (1) AU2020258002B2 (https=)
BR (1) BR112021020605A2 (https=)
CA (1) CA3136171A1 (https=)
EA (1) EA202192454A1 (https=)
ES (1) ES3012533T3 (https=)
LU (1) LU101183B1 (https=)
MX (1) MX2021012604A (https=)
WO (1) WO2020212478A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116635022A (zh) * 2020-05-20 2023-08-22 归属疗法有限公司 用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
CN119931962B (zh) * 2025-04-07 2025-08-05 北京华诺泰生物医药科技有限公司 一种人偏肺病毒的培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073123A (zh) * 2014-05-16 2017-08-18 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040237A1 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
KR20020012315A (ko) * 1999-07-16 2002-02-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2014056894A1 (en) 2012-10-08 2014-04-17 Westfaelische Wilhelms-Universitaet Muenster Mek inhibitors in the treatment of virus diseases
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) * 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073123A (zh) * 2014-05-16 2017-08-18 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIN BRUCHHAGEN等: "Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound", SCIENTIFIC REPORTS, vol. 8, no. 1, 14 June 2018 (2018-06-14), pages 2 *
MARTIN LAURE等: "PD0184264, an active metabolite of the MEK-inhibitor CI-1040 shows superior pharmacokinetics and antiviral activity against influenza virus", pages 112, Retrieved from the Internet <URL:https://evis.events/eventl28/papers/849/files/940-abstract775.pdf> *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116635022A (zh) * 2020-05-20 2023-08-22 归属疗法有限公司 用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂

Also Published As

Publication number Publication date
JP2025124703A (ja) 2025-08-26
KR20210153642A (ko) 2021-12-17
EA202192454A1 (ru) 2022-03-22
JP2022529343A (ja) 2022-06-21
LU101183B1 (en) 2020-10-16
CA3136171A1 (en) 2020-10-22
US20220193017A1 (en) 2022-06-23
AU2020258002B2 (en) 2025-12-18
AU2020258002A1 (en) 2021-11-18
ES3012533T3 (en) 2025-04-09
BR112021020605A2 (pt) 2021-12-07
EP3955908A1 (en) 2022-02-23
MX2021012604A (es) 2021-11-12
US12350244B2 (en) 2025-07-08
WO2020212478A1 (en) 2020-10-22
EP3955908C0 (en) 2025-01-22
EP3955908B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP7618276B2 (ja) ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤
AU2020256326B2 (en) Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections
CN114007598A (zh) 用于治疗病毒和细菌感染的新型mek抑制剂
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
HK40029715B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220201